Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables and specialty-testing services to the worldwide pharmaceuticals, biotherapeutics, nutraceuticals, cosmeceuticals, agrochemical, food & beverage, cannabis and other industries, has completed the initial expansion of its launch-phase manufacturing capacity. In addition, the company has completed a review of its quality systems. The company also stated that backorders of reagents and supplies needed for nano-CBD processing by PBIO’s patented UltraShear(TM) Technology platform, or UST(TM), have been received. The company is now beginning to fulfill orders it has received, with plans for initial shipping to begin the week of Oct. 2, 2023. According to the announcement, the company has 10 purchase orders in hand, valued at approximately $500,000, with expectations of closing on an additional 15 orders by the end of the year; company officials anticipate having a minimum of 50 orders within a year.
PBIO has focused on preparing for quality production and has introduced new innovations into the process, including the sourcing an innovative spray-dispensing bottle format that helps protect and maintain product sterility and stability during routine use and complements the company’s prioritization of a green/clean-label, consumer-responsive design. “PBIO has reached the inflection point that we have discussed over recent months,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “We are not just launching into the fulfilment of the hundreds of thousands of dollars in orders that we have in hand, but we are also now prepared and ready for fulfillment of the additional orders anticipated throughout the fourth quarter and beyond. While it has been a long and winding road for our team and our shareholders, the good news is that the sun is shining bright on the superhighway opening up ahead of us. UltraShear is no longer just the name of a patented, revolutionary, one-of-a kind nanoemulsification process, it is now a revenue-generating machine.”
To view the full press release, visit https://ibn.fm/fMQeW
About Pressure BioSciences Inc.
Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. Its patented enabling technology platform — Pressure Cycling Technology (“PCT”) — uses alternating cycles of pressure to control biomolecular interactions, such as cell lysis and biomolecule extraction, safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counterbioterrorism applications. PBIO has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing the company to enter the biopharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology(TM) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room-temperature-stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
